BioPharma Dive January 21, 2025
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market opportunity analysts estimate to be worth about $500 million annually.
Dive Brief:
- The Food and Drug Administration on Friday approved AstraZeneca and Daiichi Sankyo’s Datroway for use in people with a common type of breast cancer that has advanced despite two earlier lines of treatment.
- Datroway, previously known as datopotamab deruxtecan or dato dxd, is cleared for people whose breast tumors are HR-positive and HER2-negative, where in testing it was associated with a 37% reduction in the risk of progression or death compared to chemotherapy. Datroway will compete in that setting with Gilead Sciences’ Trodelvy, which gained a similar...
Today's Sponsors
Today's Sponsor